Primary Stent Placement for Hepatic Artery Stenosis After Liver Transplantation: Improving Primary Patency and Reintervention Rates

Ammar Sarwar, Christine Chen, Khalid Khwaja, Raza Malik, Kristin E. Raven, Jeffrey L. Weinstein, Amy Evenson, Salomao Faintuch, Robert Fisher, Michael P. Curry, Muneeb Ahmed – 25 October 2018 – Recent studies have reported high rates of reintervention after primary stenting for hepatic artery stenosis (HAS) due to the loss of primary patency. The aims of this study were to evaluate the outcomes of primary stenting after HAS in a large cohort with longterm follow‐up.

Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease

Nadim Mahmud, Abraham Shaked, Kim M. Olthoff, David S. Goldberg – 25 October 2018 – The 5‐year incidence of posttransplant hepatocellular carcinoma (HCC) recurrence is 8%‐20%. Several studies have evaluated pretransplant risk factors for HCC recurrence, but nearly all data have treated HCC as a homogeneous condition across all etiologies of liver disease despite differences in tumor biology and baseline incidence of HCC.

Readdressing the Middle Hepatic Vein in Right Lobe Liver Donation: Triangle of Safety

Sanjay Goja, Sanjay Kumar Yadav, Arvinder Singh Soin – 25 October 2018 – For equipoising donor safety and optimal recipient outcomes, we adopted an algorithmic “triangle of safety” approach to retrieve 3 types of right lobe liver grafts (RLGs), namely, the modified extended right lobe graft (MERLG), the partial right lobe graft (PRLG), and the modified right lobe graft (MRLG). Reconstruction to achieve a single wide anterior sector outflow was ensured in all patients.

LiverLearning®: 2018 Webinar: HBV - Update on the Guidelines and Controversies in Management

This webinar focuses on reviewing the highlights of the revised AASLD Clinical Practice Guidelines for HBV infection in the first talk.  The second presentation addresses a key area of controversy, namely the role of antiviral therapy in patients during the immunotolerant phase of chronic HBV infection.Naga P. Chalasani (Moderator) Naga P. Chalasani, MD, FAASLD currently serves as David W. Crabb Professor of Medicine and Interim Chair of the Department of Medicine at Indiana University School of Medicine.

Glypican‐3‐Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma

Ying Fu, Daniel J. Urban, Roger R. Nani, Yi‐Fan Zhang, Nan Li, Haiying Fu, Hamzah Shah, Alexander P. Gorka, Rajarshi Guha, Lu Chen, Matthew D. Hall, Martin J. Schnermann, Mitchell Ho – 24 October 2018 – Hepatocellular carcinoma (HCC) is the second most common cause of cancer‐related death in the world. Therapeutic outcomes of HCC remain unsatisfactory, and novel treatments are urgently needed.

Subscribe to